Business
Appointment of Yves Decadt as Member of Poxel’s Board of Directors
LYON, France, October 31, 2025--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today announces the appointment of Yves Decadt as a member of its Board of Directors.
About this update from Poxel Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":256,"url":"https://media.zenfs.com/en/business-wire.com/f90d435525310fb1141afb468763f2ef"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bcKuaLqAlid7QBfW2M_AXQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTUxMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/f90d435525310fb1141afb468763f2ef","width":480,"height":256}},"lazy":false},{"type":"text","content":"LYON, France, October 31, 2025--(BUSINESS WIRE)--Regulatory News:","length":65,"tagName":"p"},{"type":"text","content":"POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today announces the appointment of Yves Decadt as a member of its Board of Directors.","length":362,"tagName":"p"},{"type":"text","content":"Following the governance changes implemented on July 31, this appointment further strengthens Poxel’s strategic and commercial organization. It will be submitted for shareholder approval at the Company’s next Annual General Meeting.","length":232,"tagName":"p"},{"type":"text","content":"Yves Decadt brings over 25 years of international experience in the pharmaceutical industry. He spent nearly 20 years at Johnson & Johnson within the Global Business Development department, where he was responsible for licensing and deal negotiations, particularly across Asia. He has also held several senior executive positions in leading biopharma and medtech companies. Yves will bring to Poxel a unique combination of scientific and strategic expertise, as well as access to an extensive global network. Since August 2025, Yves has been working with Poxel’s teams under a consultancy agreement, supporting ongoing partnership discussions and conducting an in-depth assessment of the commercial development potential of Poxel’s main assets.","length":748,"tagName":"p"},{"type":"text","content":"Yves Decadt holds degrees in Bio-Engineering and Industrial Business Administration from University of Ghent (Vlerick School), as well as in Pharmacology and Pharmaceutical Medicine from the Université Libre de Bruxelles. He also hold...